Addex Therapeutics Files Form 6-K with Press Release
Ticker: ADXN · Form: 6-K · Filed: Jul 1, 2024 · CIK: 1574232
Sentiment: neutral
Topics: disclosure, press-release, filing
TL;DR
Addex Therapeutics dropped a 6-K on July 1st with a press release attached - check Exhibit 99.1 for deets.
AI Summary
On July 1, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, which is incorporated by reference into this Form 6-K filing. The press release details are not provided in this excerpt, but it is attached as Exhibit 99.1. This filing also notes that Addex Therapeutics Ltd. files annual reports under Form 20-F.
Why It Matters
This filing indicates a routine disclosure of a press release by Addex Therapeutics, which may contain important updates for investors regarding the company's operations or strategic direction.
Risk Assessment
Risk Level: low — This filing is a standard Form 6-K reporting a press release and does not contain significant new financial or operational information that would immediately alter risk.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- July 1, 2024 (date) — Date of press release and filing
- Exhibit 99.1 (document) — Attached press release
- Form 20-F (document) — Annual report form
- Form 6-K (document) — Report type
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release issued by Addex Therapeutics Ltd. on July 1, 2024, which is attached as Exhibit 99.1 and incorporated by reference.
What is the date of the press release mentioned in the filing?
The press release mentioned in the filing is dated July 1, 2024.
Which exhibit contains the press release?
Exhibit 99.1 contains the press release.
Does Addex Therapeutics file annual reports under Form 20-F or 40-F?
Addex Therapeutics files annual reports under cover of Form 20-F.
What is the company's principal executive office address?
The company's principal executive office is located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-07-01 06:05:06
Filing Documents
- f6k_070124.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-003723.txt ( ) — 14KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] On July 1, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated July 1, 2024 INCORPORATION BY REFERENCE Exhibits 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd (Registrant) Date: July 1, 2024 /s/ Tim Dyer Tim Dyer Chief Executive Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated July 1, 2024